Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Additional filters

Article Language

Species

Sex

Age

Other

Search Results

233 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Publication Date timeline is not available.
Page 1
Pembrolizumab After Two or More Lines of Previous Therapy in Patients With Recurrent or Metastatic SCLC: Results From the KEYNOTE-028 and KEYNOTE-158 Studies.
Chung HC, Piha-Paul SA, Lopez-Martin J, Schellens JHM, Kao S, Miller WH Jr, Delord JP, Gao B, Planchard D, Gottfried M, Zer A, Jalal SI, Penel N, Mehnert JM, Matos I, Bennouna J, Kim DW, Xu L, Krishnan S, Norwood K, Ott PA. Chung HC, et al. Among authors: matos i. J Thorac Oncol. 2020 Apr;15(4):618-627. doi: 10.1016/j.jtho.2019.12.109. Epub 2019 Dec 20. J Thorac Oncol. 2020. PMID: 31870883 Free article.
Capturing Hyperprogressive Disease with Immune-Checkpoint Inhibitors Using RECIST 1.1 Criteria.
Matos I, Martin-Liberal J, García-Ruiz A, Hierro C, Ochoa de Olza M, Viaplana C, Azaro A, Vieito M, Braña I, Mur G, Ros J, Mateos J, Villacampa G, Berché R, Oliveira M, Alsina M, Elez E, Oaknin A, Muñoz-Couselo E, Carles J, Felip E, Rodón J, Tabernero J, Dienstmann R, Perez-Lopez R, Garralda E. Matos I, et al. Clin Cancer Res. 2020 Apr 15;26(8):1846-1855. doi: 10.1158/1078-0432.CCR-19-2226. Epub 2019 Nov 22. Clin Cancer Res. 2020. PMID: 31757877
Efficacy and safety of pembrolizumab in patients with advanced mesothelioma in the open-label, single-arm, phase 2 KEYNOTE-158 study.
Yap TA, Nakagawa K, Fujimoto N, Kuribayashi K, Guren TK, Calabrò L, Shapira-Frommer R, Gao B, Kao S, Matos I, Planchard D, Chatterjee A, Jin F, Norwood K, Kindler HL. Yap TA, et al. Among authors: matos i. Lancet Respir Med. 2021 Jun;9(6):613-621. doi: 10.1016/S2213-2600(20)30515-4. Epub 2021 Apr 6. Lancet Respir Med. 2021. PMID: 33836153 Clinical Trial.
Evaluating radiological response in pancreatic neuroendocrine tumours treated with sunitinib: comparison of Choi versus RECIST criteria (CRIPNET_ GETNE1504 study).
Solis-Hernandez MP, Fernandez Del Valle A, Carmona-Bayonas A, Garcia-Carbonero R, Custodio A, Benavent M, Alonso Gordoa T, Nuñez-Valdovino B, Sanchez Canovas M, Matos I, Alonso V, Lopez C, Viudez A, Izquierdo M, Calvo-Temprano D, Grande E, Capdevila J, Jimenez-Fonseca P. Solis-Hernandez MP, et al. Among authors: matos i. Br J Cancer. 2019 Oct;121(7):537-544. doi: 10.1038/s41416-019-0558-7. Epub 2019 Sep 3. Br J Cancer. 2019. PMID: 31477779 Free PMC article.
Analysis of mutant allele fractions in driver genes in colorectal cancer - biological and clinical insights.
Dienstmann R, Elez E, Argiles G, Matos I, Sanz-Garcia E, Ortiz C, Macarulla T, Capdevila J, Alsina M, Sauri T, Verdaguer H, Vilaro M, Ruiz-Pace F, Viaplana C, Garcia A, Landolfi S, Palmer HG, Nuciforo P, Rodon J, Vivancos A, Tabernero J. Dienstmann R, et al. Among authors: matos i. Mol Oncol. 2017 Sep;11(9):1263-1272. doi: 10.1002/1878-0261.12099. Epub 2017 Jul 20. Mol Oncol. 2017. PMID: 28618197 Free PMC article.
The safety of ramucirumab for the treatment of colorectal cancer.
Noguerido A, Mulet-Margalef N, Matos I, Ros J, Argilés G, Élez E, Tabernero J. Noguerido A, et al. Among authors: matos i. Expert Opin Drug Saf. 2018 Sep;17(9):945-951. doi: 10.1080/14740338.2018.1506762. Epub 2018 Aug 16. Expert Opin Drug Saf. 2018. PMID: 30073902 Review.
233 results